Core Viewpoint - WuXi Biologics (02269) has issued an earnings upgrade for the second half of 2025, with revenue expected to grow by 17% year-on-year, aligning with expectations, while net profit is projected to increase by 38% to 2.6 billion RMB, significantly exceeding market forecasts [1] Financial Performance - Adjusted net profit is expected to rise by 31% to 3.7 billion RMB, also surpassing market expectations [1] - Gross margin is anticipated to increase by 6.2 percentage points to 48.8%, which is a key positive surprise in the earnings upgrade and a major driver of the better-than-expected profit performance [1] Market Position - WuXi Biologics remains a preferred stock in the Chinese Contract Research Organization (CRO) and Contract Development and Manufacturing Organization (CDMO) sectors [1]
里昂：药明生物(02269)下半财年纯利远胜预期 续列行业首选